Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities

Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities

Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-spe...

Full description

Bibliographic Details
Main Authors: Yifan Xu, Jin Jiang, Yutong Wang, Wei Wang, Haokun Li, Wenyu Lai, Zhipeng Zhou, Wei Zhu, Zheng Xiang, Zhiming Wang, Zhe Zhu, Lingfeng Yu, Xiaolan Huang, Hua Zheng, Sha Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
gynecologic malignancies
engineered T cells
CAR-T
TCR-T
adoptive T cell therapy
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.725330/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.725330/full

Similar Items